Time filter

Source Type

Nakasaki M.,IFOM inSTEM Joint Research Laboratory | Nakasaki M.,University of California at San Diego | Hwang Y.,University of California at San Diego | Hwang Y.,Soonchunhyang University | And 14 more authors.
Nature Communications | Year: 2015

Fibrosis is a pervasive disease in which the excessive deposition of extracellular matrix (ECM) compromises tissue function. Although the underlying mechanisms are mostly unknown, matrix stiffness is increasingly appreciated as a contributor to fibrosis rather than merely a manifestation of the disease. Here we show that the loss of Fibulin-5, an elastic fibre component, not only decreases tissue stiffness, but also diminishes the inflammatory response and abrogates the fibrotic phenotype in a mouse model of cutaneous fibrosis. Increasing matrix stiffness raises the inflammatory response above a threshold level, independent of TGF-β, to stimulate further ECM secretion from fibroblasts and advance the progression of fibrosis. These results suggest that Fibulin-5 may be a therapeutic target to short-circuit this profibrotic feedback loop. © 2015 Macmillan Publishers Limited. All rights reserved.


PubMed | University of California at San Diego, Kansai Medical University, Christian Medical College, IFOM inSTEM Joint Research Laboratory and Center for Stem Cell Research
Type: | Journal: Nature communications | Year: 2015

Fibrosis is a pervasive disease in which the excessive deposition of extracellular matrix (ECM) compromises tissue function. Although the underlying mechanisms are mostly unknown, matrix stiffness is increasingly appreciated as a contributor to fibrosis rather than merely a manifestation of the disease. Here we show that the loss of Fibulin-5, an elastic fibre component, not only decreases tissue stiffness, but also diminishes the inflammatory response and abrogates the fibrotic phenotype in a mouse model of cutaneous fibrosis. Increasing matrix stiffness raises the inflammatory response above a threshold level, independent of TGF-, to stimulate further ECM secretion from fibroblasts and advance the progression of fibrosis. These results suggest that Fibulin-5 may be a therapeutic target to short-circuit this profibrotic feedback loop.

Loading IFOM inSTEM Joint Research Laboratory collaborators
Loading IFOM inSTEM Joint Research Laboratory collaborators